Results 81 to 90 of about 88,356 (287)

A review of conjugation technologies for antibody drug conjugates

Antibody Therapeutics
Abstract Antibody–drug conjugates (ADCs) have gained significant attention in biotherapeutics after several years of steady development. Among the multiple factors influencing ADC design, the conjugation method is one of the most critical parameters.
Fan, Qirui, Chen, Hu, Wei, Guoguang, Wei, Ding, Wang, Zekun, Zhang, Lin, Wang, Jun, Zhu, Marie   +7 more
openaire   +2 more sources

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

Molecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov, Shiva Krishna Katkam, Zhefan Wang, Venkateshwar G. Keshamouni   +3 more
wiley   +1 more source

Antibody Conjugates via Disulfide Bridging: Towards therapeutic and diagnostic applications

, 2015
Antibodies play a prominent role in chemical and biological research and the largest application of chemical bioconjugation reagents is in the production of antibody conjugates.
Hull, EA
core  

Supplementary Fig. S2 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

, 2008
Supplementary Fig.
Eileen Turcott (15041066), Ivan Stone (15036102), Hans-Peter Gerber (4261570), Lori Westendorf (15036087), Charlotte F. McDonagh (14973178), Stephen C. Alley (1897735), Django Sussman (1934839), Martha Anderson (1934836), Paul J. Carter (3387371), Tiffany Feist (15036093), Jamie Miyamoto (15041069), Kristine M. Kim (15036084), Lindsay L. Brown (15036090), Robert Lyon (15036096)   +13 more
core   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Supplementary Material from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

, 2008
Supplementary Material from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic ...
Eileen Turcott (15041066), Ivan Stone (15036102), Hans-Peter Gerber (4261570), Lori Westendorf (15036087), Charlotte F. McDonagh (14973178), Stephen C. Alley (1897735), Django Sussman (1934839), Martha Anderson (1934836), Paul J. Carter (3387371), Tiffany Feist (15036093), Jamie Miyamoto (15041069), Kristine M. Kim (15036084), Lindsay L. Brown (15036090), Robert Lyon (15036096)   +13 more
core   +1 more source

Multiplex Bioanalytical Methods for Comprehensive Characterization and Quantification of the Unique Complementarity-Determining-Region Deamidation of MEDI7247, an Anti-ASCT2 Pyrrolobenzodiazepine Antibody–Drug Conjugate

, 2023
Deamidation, a common post-translational modification, may impact multiple physiochemical properties of a therapeutic protein. MEDI7247, a pyrrolobenzodiazepine (PBD) antibody–drug conjugate (ADC), contains a unique deamidation site, N102, located ...
Kathryn Ball, Dengfeng Liu, Robert J. Kubiak, Yue Huang, Jiaqi Yuan, Niluka de Mel, Lorin K. Roskos, Anton I. Rosenbaum, Meina Liang, Ruipeng Mu, Mingyan Cao, G. Patrick Hussmann   +11 more
core   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

AI-driven innovation in antibody-drug conjugate design

Frontiers in Drug Discovery
Antibody-drug conjugates (ADCs) represent a mechanistically defined class of targeted therapeutics that combine monoclonal antibodies with cytotoxic payloads to achieve selective delivery to antigen-expressing carcinoma cells.
Heather A. Noriega, Xiang Simon Wang
doaj   +1 more source

Supplementary Table S3 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index

, 2008
Supplementary Table S3 from Engineered anti-CD70 antibody-drug conjugate with increased therapeutic ...
Eileen Turcott (15041066), Ivan Stone (15036102), Hans-Peter Gerber (4261570), Lori Westendorf (15036087), Charlotte F. McDonagh (14973178), Stephen C. Alley (1897735), Django Sussman (1934839), Martha Anderson (1934836), Paul J. Carter (3387371), Tiffany Feist (15036093), Jamie Miyamoto (15041069), Kristine M. Kim (15036084), Lindsay L. Brown (15036090), Robert Lyon (15036096)   +13 more
core   +1 more source